ankylosing spondylitis activity, not due to treatment interruption or poor adherence, after having a sustained clinically meaningful improvement on treatment (generally, beyond the initial 6 months of treatment). Conventional synthetic antirheumatic drug Sulfasalazine, methotrexate, leflunomide, apremilast, thalidomide, pamidronate. Biosimilar Biopharmaceuticals that are copies of an original biologic medication and tested to be of the same purity and potency as the original. In these recommendations, we refer only to TNFi biosimilars. Examples include infliximab-dyyb, etanercept-szzs, and adalimumab-atto. TNFi Infliximab, etanercept, adalimumab, certolizumab, golimumab, and their biosimilars. TNFi monoclonal antibodies Infliximab, adalimumab, certolizumab, golimumab. Biologics TNFi, abatacept, rituximab, sarilumab, tocilizumab, ustekinumab, secukinumab, ixekizumab.** High-quality evidence Studies that provide high confidence in the effect estimate, and new data from future studies